In difficult-to-treat disorders, the traditional pharmacological agents or medical devices
INTRODUCTION
There are a wide variety of diseases with the multiple symptoms and disabilities as well as the complexity of biomolecular and signalling cascades; they represent intricate challenges towards the development of therapy strategies. For example, treatment of central nervous system (CNS) disorders is one of the most challenging and complex areas of medicine. Cell loss following the neural insults disrupts the connectivity and signal transmission between the neurons leading to neuronal dysfunction. Traumatic injuries to the CNS including the traumatic brain injury (TBI) and spinal cord injury (SCI) re-Hassanzadeh sult in axonal degeneration and neuronal necrosis. Following SCI, the victims are usually left paralyzed and only palliative measures are available. In TBI, pharmacological agents reduce the sequelae in the acute phase of the injury process or enhance the function of remaining brain tissue during the chronic stage but do not lead to the regeneration or replacement of damaged or necrotic nervous tissue. In general, the adult brain has a limited regenerative capacity and TBI or stroke results in a usually permanent neuronal loss and the disruption of brain parenchyma. Since SCI and TBI are multifactorial in pathophysiology, therefore, it is likely that the effective treatments require the combinations of strategies to counteract secondary injuries as well as the methods to enhance axonal re-growth, synaptic plasticity, and inhibition of astrocytosis (1, 2) . Current treatment strategies against neurodegenerative disorders focus on the minimizing of further tissue loss and/or alleviating symptoms through the administration of pharmacological agents, rehabilitation, or surgical intervention. However, these treatments usually mitigate the degeneration process and do not reverse the condition (3) . In addition, blood-brain barrier (BBB) hampers the entrance of hydrophilic drugs or large molecules into the brain (4) . Therefore, drug delivery to the CNS is a main challenge in the field of regenerative medicine (5) . The first approach to treat CNS diseases has been based on the invasive techniques of neurosurgery that deliver the drug directly to the target site (6) . This method, besides the neurosurgical costs, is associated with the increased risk of infections and low patient compliance. In addition, a temporary chemical or physical disruption of the BBB, or an osmotic shift may be used to allow the drug to cross the BBB (7) . However, the temporary disruption of the BBB results in several drawbacks such as a physiological stress or a transient increase in intracranial pressure. Furthermore, the increase of BBB permeability, even for a short time, makes the brain vulnerable to the infections. Hence, non-invasive techniques based on the modifications of physicochemical properties of drugs or conjugation of molecules with antibodies are suggested to improve drug delivery to the brain (8, 9) . The peripheral nervous system (PNS) is more accessible than the CNS, however, problems are still encountered mainly due to the poor stability and considerable side effects of many neuroactive compounds when administered systemically. Artificial transplants or transplanted organs have been used for incurable end-stage diseases or tissue loss for a long time. Such interventions are expected to be challenged by the necessity of lifelong immunosuppression or other complications.
In recent years, tissue engineering, a major component of regenerative medicine, has emerged as a rapidly expanding approach to revolutionize the ways for improving patients' quality of life through restoring, maintaining, or enhancing tissue function. In the post-injury brain, tissue engineering represents several advantages over the pharmacological strategies such as the ability to bridge the structural gaps for reconnection of neuronal processes or eliciting specific cell behaviour. In addition, guided neurite and axonal growth ensures the appropriate and regulated connectivity within the neural circuitry of brain (10) . In neurological disorders, successful cell therapies to replace lost neurons or prevent further degeneration are underpinned by several mechanisms including the vascularization, providing of cellular microenvironments for neural regeneration, and promotion of guided axonal outgrowth. These factors act cumulatively to enhance cell survival and connectivity, and re-establish a functional neuronal network (11) .
In addition to the therapeutic applications, tissue engineering is used for diagnostic screening, e.g., a tissue is made in vitro and used for the evaluation of a drug toxicity or pharmacokinetic profile (12) . Since the growth factors play an essential role in tissue repair and healing, the incorporate of these multifunctional proteins within the biomaterials as well as the their delivery systems will be discussed in further parts of this manuscript.
TISSUE ENGINEERING: THE GENERAL ASPECTS
As indicated, tissue engineering is a rapidly developing interdisciplinary field that is characterized by the convergence of disciplines such as advanced material science, biochemistry, cell biology, engineering, and medicine. Tissue engineering includes substitutive (whole organ replacement), histioconductive (replacement of missing or damaged parts of an organ with ex vivo constructs), and histioinductive (facilitation of self-repair or gene therapy) approaches (13) . In general, the goal of tissue engineering is to regenerate tissues and restore organ function through the implantation of cells or incorporation of matrices. Human tissue engineering offers tremendous promise for the improved prognosis and treatment, faster recovery, and a more biologically favourable situation that may facilitate the self-healing of body.
Medical applications of tissue engineering
These will be briefly listed below and will be further discussed in another section of the present review.
Tissue engineering and growth factors

Tissue-engineered bone
The regeneration of skeletal bone may be a major clinical need for victims of the accidents or degenerative diseases. Development of new biomimetic materials which provide a suitable microenvironment for cell-matrix interaction as well as the proliferation of differentiated osteocytes have been the focus of intense research (14) .
Tissue-engineered cartilage
Degenerative joint conditions become increasingly common with age, however, damage may also occur in young patients. Conventional treatments include partial or total joint replacements, but at present, the damaged cartilage may be replaced with a tissue engineered cartilage using the patient's own chondrocytes (15) .
Tissue-engineered myocardium
There is a number of research projects aimed at regenerating or repairing the myocardium including the development of tissue-engineered myocardial patches (16) .
Tissue-engineered peripheral nerves
When a peripheral nerve is severed, the remaining gap in the nerve ending may be too wide to be treated by the conventional microsurgery. Hence, a growing interest has been attracted towards the identification of suitable biomaterials that may provide a conduit to enable regeneration-promoting Schwann cells to grow in a guided manner to bridge the gaps (17).
Tissue-engineered skin
Cells which have been grown on a variety of substrates provide a biocompatible physical barrier against the fluid loss and infection. They may be used for the treatment of serious burns and diabetic ulcers or promote the regeneration of patient's own skin (18) .
Tissue-engineered blood vessels
Development of tissue-engineered blood vessels is one of the most exciting current challenges in reconstructive medicine. A variety of approaches are being developed using both synthetic biopolymer scaffolds and biologically-derived matrix materials that entail the incorporation of smooth muscle cells and vascular endothelial cells into a tubular scaffold in order to provide a structure similar to that of a native artery. Meanwhile, an appropriate respond to the changes of blood pressure is a particularly important characteristic for the tissue-engineered blood vessels (19) .
Tissue-engineered cornea
Since the cornea is avascular, therefore, tissue engineering of cornea is a major medical challenge. In this sense, the selection of the corneal cells, the effects of growth factors on the culture of corneal cells, and the application of suitable scaffolds appear particularly crucial (20) .
Research areas in tissue engineering
Tissue engineering includes the following research areas: (i) biomolecules; including the differentiation factors, growth factors, and other key proteins, (ii) biomaterials; which may influence the organization, growth, and differentiation of cells in the process of formation of a desired tissue, (iii) cells; which may be autologous, allogeneic, xenogeneic, or stem cells, (iv) safety and performance; including the characteristics of tissues and identification of the properties required for the engineered tissues, (v) manufacturing issues; such as cell expansion or storage, and three-dimensional (3D) tissue growth, and (vi) other aspects; including modelling, informatics, clinical data, and quality assurance (21).
The required criteria for an effective tissue engineering
A number of criteria should be satisfied in order to achieve an effective and long-lasting repair of damaged tissues such as (i) the production of an adequate number of cells in order to fill the defect, (ii) the differentiation of the cells into the desired phenotype, (iii) the produced cells should be structurally and mechanically compliant with native cells in order to overcome the risk of immunological rejection, and (iv) the specialized cells should adopt an appropriate 3D structural support and secret the extracellular matrix (22) .
Devices in tissue engineering
There are several types of devices such as (i) implant; a kind of medical device that restores or modifies the tissue function. The surface of an implant which contacts the body may be made of a biomedical material such as silicone, apatite, or titanium. Some implants such as the artificial pacemaker or cochlear implants contain electronic components and some others are consisted of bioactive substances such as the implantable pills or drug-eluting stents (23), (ii) bioreactor; a device which provides a physiological environment in order to promote cell or tissue growth. The bioreactors are designed to perform at least one of the following functions: a) promoting the uniform cell distribution, b) maintaining the desired Hassanzadeh concentration of gases in the medium, c) regulation of mass transport of nutrients to the tissue, d) exposing tissue to physical stimuli, or e) facilitating the formation of a 3D tissue (24) . Tissue engineering technologies are based on the biological triad of cells, signalling mechanisms, and extracellular matrix. In order to simulate the development of tissues in vitro, tissue engineering aims to optimize cell growth by providing regulatory signals in the form of growth factors and a regeneration template in the form of scaffold. Bioreactors may be used as an alternative to or in conjunction with growth factors in the signalling part of the triad (25), (iii) polymer matrix which controls tissue regeneration or wound healing and serves as a scaffold to support cell transplantation. Degradable polymers such as poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) and poly(e-caprolactone) (PCL) are used in surgical sutures, reconstructive implants, and drug delivery devices (26, 27) . PGA/PLA and copolymers have been widely used in artificial skin grafts for surgical repair of skin defects in plastic and reconstructive surgery (28) . In addition, PGA tubes have been successfully used as guidance channels for axonal reconnection in human PNS injuries (29) . Through the incorporation into the polymeric devices, protein structure and biological activity can be stabilized and the length of time over which the polypeptides or growth factors are released at the delivery site, is prolonged. The duration of drug release from a polymer matrix depends on polymer type, drug loading percentage, and the processing conditions (30) .
Delivery systems in tissue engineering
In tissue engineering, the delivery systems are designed in a variety of configurations and geometries. They are fabricated from different types of natural or synthetic degradable or nondegradable polymers which control the release of drugs or bioactive proteins for extended periods of time. In recent years, particle-based delivery systems have attracted a considerable interest because the engineered particles provide advantages in many aspects of drug delivery such as improvement of the solubility of poorly water-soluble compounds, prolonging the half-life of therapeutic agents in blood circulation, and delivering a drug locally or in a targeted manner to minimize side effects (31) . In order to improve drug delivery to the brain, non-invasive techniques including the nanosystems or colloidal carriers that are lipid-or polymer-based have been developed (32, 33) . Among the colloidal carriers, polymeric nanoparticles are promising candidates for CNS drug delivery. These nanoparticles encapsulate the drugs and protect them against the excretion or metabolism within the body. Moreover, they deliver therapeutic agents across the BBB without inflicting any damage to the barrier. Application of polymeric nanoparticles or waxes is one of the most promising strategies for specific and selective CNS drug delivery. In this context, different polymers including polylactideco-glycolide (PLGA), chitosan, poly(butylcyanoacrilate) (PBCA) and poly(cyanoacrylate-co-hexadecylcyanoacrylate) (PHDCA) have been used to prepare nanoparticles (34) . In addition, BBB permeabilizers, genetically engineered cells, and biodegradable or non-biodegradable polymeric devices have been developed in order to provide a continuous delivery of neuroactive agents (35, 36) .
Key materials for the development of a living construct
The major principle of tissue engineering is based on the combination of living cells with a natural or synthetic support in order to build a 3D construct which is structurally and functionally similar to the tissue that is to be replaced. The development of such a construct requires the selection of four key materials: (i) scaffold, a 3D tissue structure that guides the organization, growth, and differentiation of the cells. Scaffolds should be biocompatible and satisfy the biological requirements of a specific cell population. In this context, a biofunctionalized hybrid scaffold which plays a crucial role in the repair of damaged tissue(s), is obtained by the attachment of biomolecules such as the growth factors which direct cell development and proliferation (37) . In recent years, a variety of scaffolds have been engineered to provide an artificial microenvironment for the enhancement of cell survival and proliferation as well as the regeneration of damaged tissues. In general, an individualistic or disease-based approach is essential for the suitable scaffolding, e.g., for a successful nerve regeneration, a tissue-engineered scaffold should provide both mechanical support for growing nerves and biological signals to direct the axonal growth cone to the distal stump. For brain repair, an increasing interest has been attracted towards the construction of scaffolds and optimization of their biochemical or biophysical properties (38, 39) , (ii) extracellular matrix which should be capable of providing optimal conditions for cell adhesion, growth, and differentiation within the construct. This may be achieved by creating a system capable of controlling environmental factors such as pH, temperature, oxygen, and mechanical forces (40) , (iii) cells; development of a viable construct involves a suitable supply of cells that Tissue engineering and growth factors are non-immunogenic, highly proliferative, easy to harvest, and being able to differentiate into a variety of specialized cells. Efforts are now being undertaken for engineering different tissues and organs using the stem cells, in particular the mesenchymal stem cells which differentiate into a variety of tissues (41, 42) , and (iv) growth factors (see below).
GROWTH FACTORS: THE GENERAL ASPECTS
The term growth factor is generally used to indicate a naturally occurring substance which is able to stimulate cellular growth, proliferation, and differentiation (43) . During the natural regeneration of tissues, there is an orchestrated delivery of growth factors. For example, as soon as the blood vessels are disrupted after wound formation, platelets enter the wound in great numbers and release several growth factors including platelet-derived growth factor (PDGF) and transforming growth factor-β1 (TGF-β1) (44) . These growth factors are chemotactic for a number of cell types such as macrophages, fibroblasts, and endothelial cells which play a critical role in the repair process. During the proliferative phase of wound repair, several growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), PDGF and TGF-β isoforms provide a potent stimulus for fibroblasts to synthesize the key extracellular components, i.e., collagens, proteoglycans, fibronectin, and elastin. In the later stages of wound repair, growth factors are implicated in tissue remodelling. As the growth factors are critical for the maintenance of tissue integrity and cell to cell communication, their activities are preserved following the wound closure or tissue remodelling (45) .
Neurotrophins
Neurotrophins, a unique family of growth factors, play a key role in the connectivity and survival of neurons, the nerve growth factor (NGF) being prototypic member of the family (see Homage to Rita Levi-Montalcini in this volume of Biomedical Reviews). The cellular effects of neurotrophins are mediated by their affinity to two different receptors: the Trk receptor tyrosine kinase (TrkA-C) and p75 pan-neurotrophin receptor (p75 NTR ) as well as the downstream signalling cascades (46, 47) . Neurotrophins (NGF, BDNF, NT-3, NT-4/5, NT-6) regulate numerous neuronal functions and are implicated in the pathophysiology of a wide variety of neurodegenerative and psychiatric disorders (48) (49) (50) . The therapeutic potential of NGF in SCI and Alzheimer's disease as well as its involvement in the molecular mechanisms of cardiometabolic and autoimmune diseases has been reported (51) (52) (53) (54) (55) . In addition to its neurotrophic effects, NGF improves glucose and lipid metabolism and control energy balance and feeding behaviour, indicating its metabotrophic potential (56) . Based on our previous reports, NGF is implicated in the mechanism of action of NK receptor antagonists, psychotropic drugs, and the natural compound curcumin (57) (58) (59) (60) . Other neurotrophic factors are more widely expressed in the CNS. Brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) are highly expressed in cortical and hippocampal structures and have been linked to the survival and functioning of multiple neuronal populations. They also mediate higher-order activities such as learning and memory (61, 62) . In animal models of Parkinson's disease, Huntingson's disease, and TBI, glialderived neurotrophic factor (GDNF) and BDNF promote cell survival and integration and enhance the success of cell replacement therapy (63) (64) (65) . As previously reported, BDNF and GDNF promoted the survival of axotomized rat motoneurons when administered simultaneously (66) . Meanwhile, cerebrolysin is the only drug available for clinical use which is a mixture of different neurotrophic factors including NGF, BDNF, GDNF, and ciliary neurotrophic factor (CNTF). Several studies have demonstrated cerebrolysin-induced neuroprotection, neuroplasticity and neurogenesis (67) (68) (69) (70) . However, the short half-life, relatively large size, slow tissue penetration, and toxicity are the problems encountered in the conventional routes of administration of growth factors. Administration of insulin-like growth factor (IGF) or human growth hormone (hGH) poses many problems owing to their limited oral bioavailability and short in vivo half-lives (71) . Clinical trials using CNTF have yielded disappointing outcomes because of the side effects (72) . Therefore, an improved growth factor delivery is essential to get a better efficacy profile. The bioengineered products deliver growth factors in appropriate concentration that has been proved difficult to achieve with systemic application (73) .
Growth factors and tissue engineering
Based on the critical role of growth factors in tissue development and repair, these multifunctional peptides should be involved in the tissue engineering strategies (74) . One particular area that represents an exciting challenge in the field of tissue engineering is the repair and regeneration of cartilage. In this respect, cells for the generation of tissue, a scaffold to support the growth, and a growth factor to stimulate the correct biological signals for tissue growth and integration with Hassanzadeh native cartilage are the necessary components (75, 76) . TGF, FGF, and IGF are the main growth factors involved in chondrogenic differentiation. The TGF-β super-family includes the proteins which play an important role in the formation of cartilage. The family members including TGF-β, bone morphogenetic proteins (BMPs), inhibins and activins regulate cell growth, differentiation, and apoptosis of different cell types including osteoblasts, chondrocytes, neural and epithelial cells (77) . The FGF family regulates the proliferation, differentiation, and matrix production of articular cartilage and growth plate chondrocytes both in vivo and in vitro (78) . In IGF family, IGF-1 mediates chondrogenesis by increasing the production of proteoglycan and collagen type II (79) .
As previously reported, combination of TGF-β3 and IGF-1 elevates chondrogenic induction from human mesenchymal stem cell (80). Longobardi et al (81) evaluated the effects of IGF-1 on the chondrogenesis of bone marrow mesenchymal stem cells in either presence or absence of TGF-β signalling.
They found that IGF-1 modulates the mesenchymal stem cell chondrogenesis by stimulating the proliferation, regulating cell apoptosis and inducing the expression of chondrocyte markers. Application of IGF-1 and TGF-β1 in a bioreactor elevates the compressive and tensile biomechanical properties of the engineered tissue (82) . Furthermore, combination of growth factors promotes the efficiency of chondrocyte proliferation in the automated bioreactors (83) . It has been shown that incorporating of growth factors into the scaffold material results in chondrocyte differentiation, tissue growth, and integration with native cartilage tissue. Chitosan scaffolds associated with chondrogenic differentiation factor, BMP-6, have been successfully used in the engineering of articular cartilage (84) . In the field of bone regeneration, the concept of a bonegenerating protein was first popularized by Urist when he discovered the BMPs, the most popular molecules for bone tissue engineering (85) . The common osteogenic factors are the members of TGF-β superfamily including TGF-β1, BMP-2, BMP-7, and retinoic acid (86, 87) . VEGF has also been identified as an osteogenic factor (88). Likewise, FGF-2 is proposed as the most appropriate growth factor for inducing the osteogenic differentiation of mesenchymal stem cells. Its supportive role in ex vivo expansion of osteogenic precursors from human bone marrow was reported (89) . In general, osteoinduction may be caused by various factors such as pre-seeded osteoblasts and/or bioactive molecules incorporated into a polymer scaffold. Following the degradation, a polymer scaffold releases the incorporated growth factor with defined kinetics leading to the recruitment and differentiation of mesenchymal progenitor cells localized in the neighboring original bone tissue (90) . Engineering of osteoinductive grafts may be achieved by loading the 3D scaffolds with either BMPs or osteogenic cells. Bone matrix is a 3D scaffold for bone cells that besides providing a tissue-specific environment and architecture, serves as a reservoir of water, nutrients, cytokines, and growth factors for the bone cells. The most important non-collagenous organic constituents of bone matrix are the multi-functional proteins including osteocalcin, bone sialoprotein, osteopontin and osteonectin that are produced by bone cells and regulate bone mineralization and remodelling. Bone matrix contains several growth factors including FGFs, IGFs, PDGF, and TGF-β superfamily. These growth factors are implicated in the regulation of cell proliferation and differentiation as well as endochondral bone formation (91) . The local concentration of growth factor affects the levels of differentiation of osteoblasts. The rapid diffusion and clearance of TGF-β2 from the implant site may be overcome by binding of TGF-β2 to bovine dermal fibrillar collagen via polyethylene glycol that result in the enhancement of growth factor stability and bioactivity (92) .
Regarding growth factor delivery in bone regeneration, it has been primarily focused on the poly(α-hydroxy acid) family of polymers. Microparticles of gelatin and poly(α-hydroxy acid) have been used for growth factor delivery (74) . In animal models of bone defects, basic fibroblast growth factor (bFGF) incorporated within the cross-linked gelatin hydrogels has shown therapeutic potential (93, 94) .
In hepatic tissue engineering, studying the molecular signals that regulate the proliferation and function of hepatocytes is an attractive research area. In this sense, hepatotropic factors including epidermal growth factor (EGF), acidic fibroblastic growth factor (aFGF), hepatocyte growth factor/scatter factor (HGF/SF), and TGF-α have attracted a growing interest (95) . Hepatocytes transplanted within a synthetic degradable polymer should remain viable with retention of their differentiated phenotype. Poly(D,L-lactic-co-glycolic acid) microparticles containing EGF co-transplanted with hepatocytes in poly-(vinyl alcohol)-coated poly(L-lactic acid) scaffolds enhanced the engraftment of hepatocytes (96) . An adequate vascularisation at the transplantation site is essential. The exogenous growth factor-induced prevascularization of the implant site due to the delivery of endothelial cell growth factor (ECGF) from chitosan-albumin microspheres enhances the survival of hepatocytes (97) . The involvement of FGF for an appropriate Tissue engineering and growth factors vascularization of the transplant has been shown (98) .
Growth factors are also implicated in the tissue engineering of skin. PDGF, TGF-α, TGF-β, and b-FGF are the major constituents of bioengineered products for the treatment of a variety of chronic skin wounds, venous ulcers, or diabetic foot ulcers (99, 100) . Regarding the implication of growth factors in the tissue-engineered myocardium, nanofiber scaffolds including VEGF has been shown to create a microenvironment for arteriogenesis and cardiac repair (101) . Moreover, HGFtransfected skeletal myoblasts limit the development of postinfarction heart failure (102). In corneal tissue-engineering, TGF-β3 has been shown to regulate the assembly of a nonfibrotic matrix in a 3D corneal model (103) and EGF is a major constituent of tissue-engineered cornea (104) .
GROWTH FACTORS AND BIOMATERIALS
The regularly applied biomaterials in tissue engineering are solid synthetics or hydrogel-type substances (105) . Matrigel, an extracellular matrix which contains laminin, fibronectin and proteoglycans, stimulates cell proliferation and preserves the typical morphological features of olfactory ensheathing cells, Schwann cells, and bone marrow stromal cells. Besides the promoting of neuronal growth in dorsal root ganglia, matrigel serves as a scaffold for in vivo delivery of Schwann cells (106) . Purified Schwann cells were mixed with matrigel and inserted in semipermeable non-degradable polyacrylonitrile/polyvinylchloride (PAN/PVC) copolymer guidance channels (107) . This construct was used to bridge a transected rat spinal cord and the following electrophysiological evaluation confirmed the functionality of regenerating axons. The combination of matrigel with VEGF or a replication-defective adenovirus coding for VEGF decreased the retrograde degeneration of axons in the corticospinal tract and increased axonal regenerative activities in rats (108) . Moreover, implantation of matrigelcontained PAN/PVC guidance channels which are enriched with GDNF promotes axonal regeneration and myelination following SCI (109) .
The fibrous aggregates of plasma fibronectin, an extracellular matrix which is involved in a variety of cellular processes including the tissue repair, embryogenesis, blood clotting, and cell migration/adhesion (110), have been used to make fibronectin mats which contain pores oriented in a single direction. Incubation of fibronectin mats with BDNF and NT-3 increases the neurofilament-positive and glutaminergic fibres. Moreover, incorporation of NGF into these mats elevates the number of calcitonin gene-related peptide (CGRP)-positive neurons (111) . Implantation of fibronectin mats impregnated with NT-3 after the transection of sciatic nerve in rat, promoted the regeneration of peripheral nerves and neuromuscular interaction (112) .
Alginate, a linear polysaccharide, has been used as a scaffold to fill the cavity in the damaged spinal cord because of its biocompatibility, hydrophilicity, and low toxicity (113) . Alginate sponge as a 3D scaffold is beneficial for the transplantation of hippocampus-derived neurosphere cells into the injured spinal cord in rat (114) . BDNF-producing fibroblasts encapsulated within alginate contributed to the functional recovery after SCI (115) . Microencapsulation of fibroblasts producing BDNF in alginate-poly-L-ornithine is another method for application of alginate in the treatment of SCI. Microcapsules protect fibroblasts from the host immune response, therefore, eliminate the need for immunosuppressive therapy (116) . Microencapsulation preserves the biological activity of growth factors as well. In the case of microencapsulation, BDNF and NGF retain their biological activity for at least 30 days (117, 118) .
Application of the water-soluble surfactant polyethylene glycol (PEG) to the site of injury in the spinal cord has been shown to seal and repair the breaches in cell membrane, reverse the injury-induced permeabilization of the membrane, inhibit the production of free radicals, and reduce the oxidative stress (119) (120) (121) . The conjugation of growth factors with PEG improves their plasma pharmacokinetics and facilitates the transport of growth factors across the BBB (122, 123) . FGF and VEGF may be covalently or noncovalently bound to a variety of materials including PEG to induce the proliferation, differentiation, adhesion, and spreading of embryonic stem cells (124) .
Among the bioengineered products, fibrin-based scaffolds have gained increasing popularity. Fibrin which acts as a natural matrix for tissue regeneration, is non-toxic and biodegradable and enhances the effects of cell-scaffold constructs. Interestingly, fibrin may be produced using a patient's own blood supply. Fibrin gels may be used in neural or cardiovascular tissue engineering (125) (126) (127) . In the area of peripheral nerve regeneration, the performance of fibrin-based scaffolds is enhanced due to the incorporation of bFGF which promotes nerve extension (128) . Meanwhile, fibrin is usually enriched with aFGF. Fibrin containing aFGF has been applied to the both ends of Schwann cells/matrigel cables in PAN/PVC guidance channels leading to the enhancement of sprouting in the corticospinal tracts (129) . Synthetic hydrogels such as Hassanzadeh poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) (PHEMA/ PHEMA-MMA) tubes with excellent mechanical integrity, have induced nerve regeneration when filled with fibrin and FGF-1 (130) . Implantation of PHEMA sponge into the cavity of the injured spinal cord has shown axonal re-growth after contusion SCI in rat (131) . Moreover, inclusion of growth factors within the PHEMA-MMA hydrogel guidance channels improved specific supraspinal and local axonal regeneration after the transection of spinal cord (132) .
In an attempt to fabricate nerve guidance scaffolds, freezedried agarose scaffolds containing NGF have been shown to promote axonal regeneration following SCI (133) . In addition, collagen gels may be used for the localized delivery of therapeutic agents after SCI. Subarachnoid-injected collagen gels deliver growth factors leading to the proliferation of progenitor cells in the injured spinal cord (134) . The combination of collagen gels with NT-3 or BDNF have been shown to stimulate the regeneration of axons in the corticospinal tract and promote functional recovery in rat model of spinal cord transaction (135, 136) . Moreover, grafts of poly(D,L-lactic acid) scaffolds impregnated with BDNF enhance the axonal regeneration of transected spinal cord (137) . In recent years, poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA), linear and water-swellable cross-linked polymers, have been developed for drug delivery or gene therapy (138) . Combination of BDNF-and CNTF-producing fibroblasts with PHPMA hydrogel grafts promotes axonal re-growth following brain injury in rat (139) . The capacity of multifunctional growth factor CNTF to rescue axotomized motoneurons and prevent their degeneration has been shown in animal models of degenerative motoneuron disorders (141, 142) . raising hope that CNTF may be used for the treatment of patients with degenerative motoneuron disorders such as amyotrophic lateral sclerosis (ALS). In this respect, clinical studies on the patients with ALS started, however, the initial encouraging reports could not be consolidated and the presence of side effects including cachexia, fever, and reactivation of herpes simplex virus resulted in the termination of clinical trials (143) (144) (145) . In addition, subcutaneously administered CNTF accumulate preferentially in the liver, therefore, the systemic application of CNTF is unlikely to make it optimally available in motor neuron diseases. Based on the tissue engineering strategies, CNTF or CNTF-secreting genetically-engineered cells may be microencapsulated that depending on the method of encapsulation and choice of polymer, the biologically active CNTF will be available for different periods of times. Microencapsulated CNTF has been shown to promote neuronal survival and nerve outgrowth in the cultures of ciliary ganglia, indicating its biological stability. Moreover, microencapsulated CNTF may offer a less invasive and effective mode of delivery than permanently installed cannulae. According to the relatively small dimensions of microspheres containing CNTF, they can be injected intrathecally, thereby, avoiding toxic effects of CNTF in the liver (146) .
Delivery of growth factors
A growth factor which is released from a delivery device may influence the regeneration of damaged tissue or enhance the engraftment and function of co-delivered cells. Meanwhile, the type of growth factor, dosage, and release profile should be optimized for an efficient delivery. Regarding the mechanisms of release, a growth factor directly incorporated into a bioresorbable polymer scaffold is released by a diffusion-controlled mechanism (147) . Alternatively, the growth factor delivery device in the form of microparticles, nanoparticles, fibers or injectable complexes can be incorporated into a suitable scaffold. A growth factor may also be released by an erosion mechansim or a combination of diffusion and erosion (148) . Hydrogel formulations have been presented for the localized delivery of growth factors. Matrix metalloproteinase (MMP)-sensitive hydrogels may be used for the targeted release of growth factors such as VEGF which improves the vascularization in the engineered constructs (149, 150) . Controlled release of growth factors that is essential for a variety of tissue engineering applications, may be achieved by different methods such as delivery from polymeric microspheres, discs, minipumps or transplanted cells. In this context, polymer matrices such as poly(-ethylene-co-vinyl acetate) and microparticles of poly(D,L-lactic-co-glycolic acid) have been developed (151, 152) . The nanoporous peptide particles which are used for encapsulating and releasing of growth factors, are considered as a promising therapeutic approach in neurodegenerative disorders (153) . Combination of cell transplantation and growth factor delivery for the treatment of neurodegenerative diseases has been proposed (154) . In addition, macrocapsules prepared by filling the preformed poly(acryonitrile-co-vinyl chloride) hollow fibre tubular structures with cells, have been used as a continuous source of growth factors for the treatment of neurodegenerative diseases (155) . Further, NGF prevents the degeneration of dopaminergic neurons and slows down the progression of Parkinson's disease (156, 157) ; however, NGF similar to other neurotrophic factors does not significantly Tissue engineering and growth factors penetrate the BBB. Therefore, the clinical significance of NGF will depend on the application of a suitable carrier system which enhances NGF transport across the BBB. A number of studies have shown that drug delivery to the brain is considerably enhanced by prior binding of the drug to poly(butyl cyanoacrylate) (PBCA) nanoparticles that are overcoated with polysorbate-80 (158, 159) . Polysorbate 80-coated PBCA nanoparticles have been proposed as an effective carrier system for NGF transport across the BBB following the intravenous injection. This approach may improve the effectiveness of NGF-based therapy in age-related neurodegenerative diseases (160) . At present, the therapeutic potential of VEGF-loaded PBCA nanoparticles in an experimental model of traumatic brain injury is evaluated in our laboratory. Conjugation of NGF with dextran has been shown to improve the penetration of NGF into the brain and elevates its retention (161) . In addition, conjugation of NGF with PEG (PEGylation) is another means by which the stability and effectiveness of NGF are enhanced (162) . Encapsulation of PEGylated VEGF into the polysorbate-80 coated PBCA nanoparticles as the drug delivery system as well as the evaluation of VEGF release profile and its biological activity are currently performed in our laboratory.
Growth factors and cell therapy
Cell therapy, a sub-type of regenerative medicine, is based on the introducing of cells into a tissue in order to treat a disease. It has been found to initiate the restoration of neurological cells in the damaged site and facilitate cognitive function. In animal models of SCI, application of the olfactory ensheathing cells; the glial cells ensheathing the axons of the olfactory receptor neurons, has resulted in the spinal cord repair (163, 164) . The regenerative capability of olfactory ensheathing cells is mainly due to the secretion of growth factors such as VEGF, NGF, BDNF, and GDNF (165, 166) . Implantation of activated macrophages results in the partial recovery in paraplegic rats (167) . Moreover, activated macrophages improve motor recovery and reduce spinal cyst formation in the experimental model of SCI (168) . The increased production of BDNF appears to be involved in the neuroregenerative potential of macrophages (169) . Following SCI, the remyelinating capability of Schwann cells and the functionality of the myelin in the conduction of neural impulses have been demonstrated (170, 171) . Schwann cells promote axonal regeneration by secretion of adhesion molecules, extracellular matrix, and a number of growth factors such as FGF-2, NGF, BDNF, and NT-3 (172) (173) (174) .
Following the transection of rat spinal cord, combination of cultured Schwann cells with FGF-1, NT-3 or BDNF induces a remarkable anatomical connectivity and functional recovery in severed axons (175) . Transplanted Schwann cells within the semipermeable poly(acryonitrile-co-vinyl chloride) polymer tubes which are used as guides for peripheral nerve regeneration, promoted neuronal regeneration when BDNF and NT-3 were infused simultaneously (176) . Genetically modified NGF-secreting neural stem cells survived and acquired phenotypic characteristics of early nerve cells when grafted into the injured adult rat brain (177) . Moreover, the regenerative effects of encapsulated cells secreting NGF have been reported (178, 179) . Likewise, NGF delivered from the polymer-encapsulated genetically-modified baby hamster kidney cells (BHK) promotes the survival of axotomized septal cholinergic neurons (180) . In addition, BHK cells have been genetically modified to secrete GDNF or CNTF for the treatment of Parkinson's disease (181) and ALS (182, 183) . In recent years, the knowledge of adipobiology has recognized the adipose tissue as the major endocrine and paracrine organ of the human body (184) . Based on the regenerative potential of adipose-derived stem cells (ADSC), neurodegenerative (185, 186) and cardiovascular (187) diseases may be targets for ADSC-based therapies.
CONCLUSION
The recent advances in tissue engineering have resulted in the development of a novel set of tissue repair or replacement strategies. The remarkable advances in stem cells research, biomimetic environments, biomaterials, and growth factors have created unique opportunities to combine the specialized cells with engineered extracellular matrices and biologically active molecules in order to fabricate tissues. There are strong links between the tissue engineering and drug delivery systems. Experiments have shown that growth factors delivered from a device promote the engraftment and function of co-delivered cells and regeneration of damaged tissues. In this context, there is an increasing interest for the development of more sophisticated growth factor delivery mechanisms in order to mimic the endogenous profiles of growth factor production during natural tissue morphogenesis or regeneration. A major challenge in tissue engineering is the need for more functionality and biomechanical stability in laboratory-grown tissues destined for transplantation. Further evidence for the development of intelligent biomaterials delivering growth factors to the injured tissue are expected.
